Key Points
- Allison Swartz sold 530 shares on Dec. 4 at an average price of $24.59 for $13,032.70; she now holds 72,719 shares, a 0.72% reduction in her ownership.
- Progyny beat quarterly estimates with EPS of $0.45 vs. $0.39 and revenue of $313.35M vs. $299.23M, and issued FY2025 guidance of $1.79–$1.82 EPS.
- Wall Street view is cautiously positive: the stock carries an average "Moderate Buy" rating with a $27.50 target, and trades with a $2.13B market cap and a 39.21 P/E.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) EVP Allison Swartz sold 530 shares of the business's stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $24.59, for a total transaction of $13,032.70. Following the completion of the transaction, the executive vice president owned 72,719 shares of the company's stock, valued at $1,788,160.21. This represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Progyny Stock Performance
Progyny stock opened at $24.70 on Tuesday. The stock has a market cap of $2.13 billion, a PE ratio of 39.21, a price-to-earnings-growth ratio of 1.89 and a beta of 0.96. The stock has a 50-day moving average of $22.11 and a two-hundred day moving average of $22.26. Progyny, Inc. has a one year low of $13.86 and a one year high of $27.51.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.06. The company had revenue of $313.35 million during the quarter, compared to analysts' expectations of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The firm's revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. As a group, sell-side analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on PGNY shares. Barclays began coverage on shares of Progyny in a research report on Monday. They issued an "overweight" rating and a $29.00 target price on the stock. Canaccord Genuity Group lifted their target price on shares of Progyny from $23.00 to $26.00 and gave the company a "hold" rating in a report on Monday, November 17th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Progyny in a research note on Wednesday, October 8th. KeyCorp raised Progyny from a "sector weight" rating to an "overweight" rating and set a $30.00 price target for the company in a report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. upped their target price on Progyny from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $27.50.
View Our Latest Research Report on PGNY
Hedge Funds Weigh In On Progyny
A number of hedge funds have recently made changes to their positions in PGNY. California State Teachers Retirement System grew its position in Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company's stock valued at $1,549,000 after acquiring an additional 457 shares during the period. Leibman Financial Services Inc. raised its position in shares of Progyny by 1.1% in the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company's stock valued at $1,011,000 after purchasing an additional 513 shares in the last quarter. Teza Capital Management LLC grew its position in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company's stock worth $221,000 after buying an additional 516 shares in the last quarter. Aristides Capital LLC increased its stake in shares of Progyny by 4.6% in the third quarter. Aristides Capital LLC now owns 11,938 shares of the company's stock worth $257,000 after buying an additional 528 shares during the last quarter. Finally, Oxford Asset Management LLP raised its holdings in Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company's stock valued at $284,000 after acquiring an additional 531 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.
Progyny Company Profile
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
